Ensysce Biosciences, Inc.
For the period ended Mar 31, 2026. Filed May 15, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Mar 31, 2026 · Filed May 15, 2026
ENSC$0.36-0.4%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Changes in Stockholders’ Equity (Deficit)
| Stockholders’ Equity (Deficit) | |||||||||
|---|---|---|---|---|---|---|---|---|---|
| Preferred Stock · Common Stock · Additional | |||||||||
| Number of Shares · Amount · Number of Shares · Amount · Paid-In Capital · Accumulated Deficit · Noncontrolling interests · Total | |||||||||
| Balance on December 31, 2024 | - | $ | - | 1,355,773 | $136 | $133,252,585 | $(129,544,299) | $(328,483) | $3,379,939 |
| Public offering | - | - | 239,594 | 24 | 1,099,982 | - | - | 1,100,006 | |
| Issuance of common stock upon exercise of warrants | - | - | 49,361 | 5 | 347,990 | - | - | 347,995 | |
| Transaction costs associated with public offering | - | - | - | - | (204,193) | - | - | (204,193) | |
| Consultant compensation | - | - | - | - | 26,093 | - | - | 26,093 | |
| Stock-based compensation | - | - | - | - | 16,251 | - | - | 16,251 | |
| Net loss | - | - | - | - | - | (1,945,573) | - | (1,945,573) | |
| Balance on March 31, 2025 | - | $ | - | 1,644,728 | $165 | $134,538,708 | $(131,489,872) | $(328,483) | $2,720,518 |
| Balance on December 31, 2025 | 3,305 | $ | - | 4,574,977 | $459 | $142,933,260 | $(139,719,999) | $(328,970) | $2,884,750 |
| Conversions of preferred stock into common stock | (1,900) | - | 4,702,842 | 470 | (470) | - | - | - | |
| Transaction costs associated with Series B Preferred Stock | - | - | - | - | (6,090) | - | - | (6,090) | |
| Stock-based compensation | - | - | - | - | 8,743 | - | - | 8,743 | |
| Net loss | - | - | - | - | - | (3,556,415) | - | (3,556,415) | |
| Balance on March 31, 2026 | 1,405 | $ | - | 9,277,819 | $929 | $142,935,443 | $(143,276,414) | $(328,970) | $(669,012) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.